A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

Trial Profile

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs AZD 4547 (Primary) ; Durvalumab (Primary) ; Palbociclib (Primary) ; Rilotumumab (Primary) ; Taselisib (Primary) ; Docetaxel; Erlotinib
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms Lung-MAP
  • Most Recent Events

    • 21 Nov 2017 Planned End Date changed from 1 Apr 2025 to 1 Apr 2022.
    • 10 Jun 2017 Biomarkers information updated
    • 27 Oct 2016 According to an AstraZeneca media release, the pivotal data is anticipated in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top